دورية أكاديمية
Durability and extent of protection of SARS-CoV-2 antibodies among patients with COVID-19 in Metro Manila, Philippines.
| العنوان: | Durability and extent of protection of SARS-CoV-2 antibodies among patients with COVID-19 in Metro Manila, Philippines. |
|---|---|
| المؤلفون: | Gonzales MLAM; Department of Pediatrics, College of Medicine, University of the Philippines Manila, Manila, Philippines., Dans LF; Department of Pediatrics, College of Medicine, University of the Philippines Manila, Manila, Philippines.; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Tan-Lim CSC; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Uy E; Asia-Pacific Centre for Evidence-Based Healthcare, Manila, Philippines., Cutiongco-Dela Paz E; Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Manila, Philippines., Sulit MVV; Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila, Philippines., Alejandria MM; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Lansang MAD; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Dans AL; College of Medicine, University of the Philippines Manila, Manila, Philippines., Dator MA; Department of Pediatrics, College of Medicine, University of the Philippines Manila, Manila, Philippines., Cordero CP; Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines., Pardilla GF; Manila Health Department Delpan Evacuation Center Quarantine Facility, Manila, Philippines. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Jun 28; Vol. 14, pp. 1190093. Date of Electronic Publication: 2023 Jun 28 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | COVID-19*, Humans ; SARS-CoV-2 ; COVID-19 Vaccines ; Philippines/epidemiology ; Cohort Studies ; Reinfection ; Antibodies, Viral |
| مستخلص: | Introduction: Information on the magnitude and durability of humoral immunity against COVID-19 among specific populations can guide policies on vaccination, return from isolation and physical distancing measures. The study determined the durability of SARS-CoV-2 antibodies after an initial infection among Filipinos in Metro Manila, Philippines, and the extent of protection SARS-CoV-2 antibodies confer against reinfection. Methods: We conducted a cohort study to monitor the antibody levels of patients diagnosed with COVID-19. Receptor-binding domain (RBD)-specific antibodies were measured at Days 21, 90, 180, 270 and 360. Antibody levels were reported as geometric mean titers (GMT) with geometric standard deviation (GSD). Differences in GMT were tested using Friedman test and Kruskal Wallis test, with Bonferroni multiple comparisons procedure. Adjusted hazard ratios on the development of probable reinfection were estimated using Cox proportional models. Results: There were 307 study participants included in the study, with 13 dropouts. Study participants received SARS-CoV-2 vaccines at varying times, with 278 participants (90.5%) fully vaccinated by the end of study. The GMT of the study cohort increased over time, from 19.7 U/mL (GSD 11) at Day 21; to 284.5 U/mL (GSD 9.6) at Day 90; 1,061 U/mL (GSD 5.3) at Day 180; 2,003 U/mL (GSD 6.7) at Day 270; and 8,403 U/mL (GSD 3.1) at Day 360. The increase was statistically significant from Day 21 to Day 90 (p<0.0001), Day 90 to Day 180 (p=0.0005), and Day 270 to Day 360 (p<0.0001). Participants with more severe initial infection demonstrated significantly higher antibody levels compared to those with milder infection at Day 21. Sixty-four patients had probable COVID-19 reinfection (incidence of 20.8%, 95% CI 16.4, 25.8%). The GMT of these 64 patients was 411.8 U/mL (GSD 6.9) prior to the occurrence of the probable reinfection. Majority (87.5%) were fully vaccinated. Antibody titers significantly affected the risk of developing reinfection, with adjusted hazard ratio of 0.994, 95% CI 0.992-0.996, p<0.001. Conclusion: Antibody levels against SARS-CoV-2 increased over a one-year follow-up. Higher antibody levels were observed among those with more severe initial infection and those vaccinated. Higher antibody levels are associated with a lower risk of probable reinfection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Gonzales, Dans, Tan-Lim, Uy, Cutiongco-dela Paz, Sulit, Alejandria, Lansang, Dans, Dator, Cordero and Pardilla.) |
| References: | J Immunol Methods. 2021 Jul;494:113060. (PMID: 33915155) Trop Med Health. 2022 Oct 11;50(1):75. (PMID: 36221142) J Virus Erad. 2021 Sep;7(3):100054. (PMID: 34548928) Arch Pathol Lab Med. 2022 Jul 1;146(7):814-821. (PMID: 35380612) Emerg Microbes Infect. 2020 Dec;9(1):1269-1274. (PMID: 32515684) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Viruses. 2021 Nov 19;13(11):. (PMID: 34835119) Nat Commun. 2021 Aug 17;12(1):4984. (PMID: 34404803) EClinicalMedicine. 2021 Nov;41:101174. (PMID: 34746725) PLoS One. 2022 Mar 10;17(3):e0265236. (PMID: 35271669) Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689) Sci Rep. 2022 Feb 16;12(1):2628. (PMID: 35173254) PLoS Pathog. 2021 Dec 28;17(12):e1010211. (PMID: 34962970) Blood Transfus. 2008 Jan;6(1):37-45. (PMID: 18661922) Viruses. 2021 May 22;13(6):. (PMID: 34067349) Open Forum Infect Dis. 2022 May 20;9(7):ofac262. (PMID: 35855960) Mil Med Res. 2021 Aug 31;8(1):47. (PMID: 34465396) PLoS One. 2022 Jan 4;17(1):e0262164. (PMID: 34982800) PLoS One. 2022 Dec 5;17(12):e0268145. (PMID: 36469505) BMC Med. 2021 Aug 23;19(1):208. (PMID: 34420521) J Infect. 2022 Nov;85(5):545-556. (PMID: 36089104) N Engl J Med. 2021 Dec 23;385(26):2487-2489. (PMID: 34818474) Front Immunol. 2022 Jan 31;13:830710. (PMID: 35173741) J Inflamm Res. 2021 Aug 29;14:4233-4243. (PMID: 34511964) JAMA Netw Open. 2022 Jan 4;5(1):e2142210. (PMID: 34994793) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; antibody; humoral response; reinfection |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (Antibodies, Viral) |
| SCR Disease Name: | COVID-19 reinfection |
| تواريخ الأحداث: | Date Created: 20230717 Date Completed: 20230718 Latest Revision: 20230718 |
| رمز التحديث: | 20230718 |
| مُعرف محوري في PubMed: | PMC10338854 |
| DOI: | 10.3389/fimmu.2023.1190093 |
| PMID: | 37457735 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1190093 |